Search hospitals > Utah > Provo
Utah Valley Regional Medical Center
Claim this profileProvo, Utah 84604
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Adenocarcinoma
258 reported clinical trials
12 medical researchers
Summary
Utah Valley Regional Medical Center is a medical facility located in Provo, Utah. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Adenocarcinoma and other specialties. Utah Valley Regional Medical Center is involved with conducting 258 clinical trials across 366 conditions. There are 12 research doctors associated with this hospital, such as Nicholas DiBella, Ramya Thota, Vilija N. Avizonis, and Grant K. Hunter.Area of expertise
1Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
103 reported clinical trials
193 drugs studied
Ramya ThotaIntermountain Medical Center7 years of reported clinical research
Studies Colorectal Cancer
Studies Adenocarcinoma
4 reported clinical trials
24 drugs studied
Vilija N. AvizonisIntermountain Medical Center10 years of reported clinical research
Studies Cancer
Studies Nasopharyngeal Cancer
3 reported clinical trials
10 drugs studied
Grant K. HunterUtah Valley Regional Medical Center7 years of reported clinical research
Studies Meningioma
Studies Brain Tumor
3 reported clinical trials
7 drugs studied
Clinical Trials running at Utah Valley Regional Medical Center
Non-Small Cell Lung Cancer
Prostate Cancer
Lung Cancer
Breast Cancer
Bladder Cancer
Meningioma
Cancer
ALK Gene Rearrangement
Multiple Myeloma
Prostate Adenocarcinoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Genetic Testing
for Early-Stage Lung Cancer
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Utah Valley Regional Medical Center?
Utah Valley Regional Medical Center is a medical facility located in Provo, Utah. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Adenocarcinoma and other specialties. Utah Valley Regional Medical Center is involved with conducting 258 clinical trials across 366 conditions. There are 12 research doctors associated with this hospital, such as Nicholas DiBella, Ramya Thota, Vilija N. Avizonis, and Grant K. Hunter.